Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Public ClinicalTrials.gov record NCT05743244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Study identification
- NCT ID
- NCT05743244
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2023
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2027
- Last update posted
- May 28, 2026
2023 – 2027
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Orange County | Orange | California | 92868 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| University of California- San Francisco | San Francisco | California | 94143 | — |
| Barbara Davis Center at University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06511 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of South Florida Diabetes Center | Tampa | Florida | 33612 | — |
| Emory Children's Center | Atlanta | Georgia | 30322 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| University of Louisville Pediatric Endocrinology | Louisville | Kentucky | 40202 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| The Children's Mercy Hospital | Kansas City | Missouri | 64111 | — |
| UBMD Pediatrics | Buffalo | New York | 14203 | — |
| Columbia University-Naomi Berrie Diabetes Center | New York | New York | 10032 | — |
| Joslin Center at SUNY Upsate | Syracuse | New York | 13210 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15224 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
| Benaroya Research Institute | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
Recently updated Diabetes Mellitus, Type 1 trials
Other public records listing Diabetes Mellitus, Type 1. Sorted by last update posted; newest first. Not a recommendation.
- NCT05478707: Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes Recruiting
- NCT05849753: Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes Recruiting
- NCT06880835: Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery Recruiting
- NCT07222332: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Recruiting
- NCT07222137: A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Recruiting
- NCT06546930: Device Use Reimagined Through Education And Mentorship Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05743244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Jul 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05743244 live on ClinicalTrials.gov.